Canadian Manufacturing

Aurora Cannabis announces EU-GMP certification at a European production facility

by CM Staff   

Exporting & Importing Financing Manufacturing Regulation Risk & Compliance Sales & Marketing Alcohol & Cannabis cannabis manufacturing In Focus Manufacturing regulation risk sales supply chain trade

The new production facility in Leuna, Saxony-Anhalt, Germany adds to the company's pan-European network of EU-GMP facilities.

EDMONTON — Aurora Cannabis Inc., a Canadian cannabis manufacturer, announced the company has received EU-GMP certification for its medical cannabis production facility in Germany. As a manufacturer of medical cannabis, achieving EU-GMP certification of the company’s first German manufacturing site marks a milestone in the fulfillment of an awarded tender by the German Federal Institute for Drugs and Medical Devices (BfArM).

The new production facility in Leuna, Saxony-Anhalt, Germany adds to the company’s pan-European network of EU-GMP facilities supplying cannabis flower and extracts for medical use by patients across existing and expanding markets. Germany’s medical cannabis market currently serves approximately 100,000 patients, representing only 0.1% of the population. In mature medical cannabis markets like Canada, market penetration is upwards of 1%, therefore the German market has significant potential for growth.

“With the EU-GMP certification of our first German site, we once again demonstrate Aurora’s excellence and leadership in establishing the necessary infrastructure to compete in the global cannabis market,” said Miguel Martin, CEO of Aurora Cannabis. “As a leading provider of medical cannabis in Germany and several other European markets, we are eager to accelerate patient access to high-quality, reliable cannabis produced in accordance with the most stringent criteria. Our first shipment from our world class Leuna facility will deliver on our commitment to the German regulatory authority and expanding patient base, a significant step in our ongoing commitment to international market growth.”

Aurora was awarded a tender/contract in 2019 by the German Federal Institute for Drugs and Medical Devices (BfArM) for the annual production of 1,000 kg of high-quality medical cannabis flower over a period of four years. The first shipment from Aurora Leuna to German pharmacies is expected via the state’s cannabis agency later this month.


Martin continued “As a leading provider of cannabis flower and extracts in Germany, we are excited by the possibility of growth in the market. Our investment in domestic production with the highest quality standards will help advance patient access to high-quality cannabis. I congratulate our team in Germany on achieving this important milestone for our Leuna facility and the commencement of local production in this critical market.”


Stories continue below